A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Inclusion Criteria
Age ≥ 45 years at screening.
BMI of ≥ 27.0 kg/m^2 at screening.
History of Atherosclerotic Cardiovascular Disease (ASCVD) with a documented history of at least one of the following:
Exclusion Criteria
History of any of the following within 60 days before screening or between screening and randomization: MI, hospitalization for unstable angina, arterial revascularization (eg, coronary, cerebrovascular or peripheral) major cardiovascular surgery, stroke, or transient ischemic attack (TIA).
New York Heart Association (NYHA) class IV HF during screening or hospitalization for HF within 60 days before screening or between screening and randomization.
Type 1 DM, or any other type of diabetes with the exception of T2DM or prior gestational diabetes. Participants with a history of gestational diabetes should be stratified according to their current diabetes classification.
For participants with T2DM (including those without a prior history of T2DM but with a HbA1c ≥ 6.5% during screening):
Use of any glucagon-like peptide-1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days before randomization or planned use during the conduct of the trial.
History of chronic pancreatitis or history of acute pancreatitis in the 180 days before screening or between screening and randomization.
Family (first-degree relative[s]), or personal history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN-2).
Calcitonin ≥ 50 ng/L (pg/mL) at screening.
Acute or chronic hepatitis; signs and symptoms of any liver disease other than metabolic dysfunction-associated steatotic liver disease, or alanine aminotransferase (ALT) > 3.0 x the upper limit of normal (ULN) during screening, or total bilirubin (TBL) > 1.8 x ULN during screening (for participants with a known diagnosis of Gilbert syndrome, direct bilirubin should be used instead of TBL).
History of malignancy within the last 5 years before screening or between screening and randomization (except for the following treated with curative intent: non-melanoma skin cancer, breast ductal carcinoma in situ, cervical carcinoma in situ, or prostate cancer in situ).
Participants of childbearing potential planning to become pregnant while on study or unwilling to use protocol-specified methods of contraception during treatment.
medinfo@amgen.com866-572-6436
Huntington Park, California 90255, United States
Palm Beach Gardens, Florida 33410, United States
Canton, Georgia 30114, United States
Arlington Heights, Illinois 60005, United States
Maplewood, Minnesota 55109, United States
Kansas City, Missouri 64114, United States
Powell, Tennessee 37849, United States
CABA, Buenos Aires 1120, Argentina
CABA, Buenos Aires 1178, Argentina
CABA, Buenos Aires C1012AAY, Argentina
CABA, Buenos Aires C1023AAB, Argentina
CABA, Buenos Aires C1060ABN, Argentina
CABA, Buenos Aires C1407GTN, Argentina
CABA, Buenos Aires C1425AGC, Argentina
CABA, Buenos Aires C1426ABP, Argentina
CABA, Buenos Aires C1426ABP, Argentina
CABA, Buenos Aires C1430CKE, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1056ABI, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1061AAT, Argentina
Mar del Plata, Buenos Aires B7600DHK, Argentina
Mar del Plata, Buenos Aires B7600FZN, Argentina
Ramos Meija, Buenos Aires B1704ETD, Argentina
San Nicolás de los Arroyos, Buenos Aires 2900, Argentina
Santa Rosa, La Pampa Province L6304BWE, Argentina
CABA, C1440AAD, Argentina
La Louvière, 7100, Belgium
Yvoir, 5530, Belgium
Fortaleza, Ceará 60430-350, Brazil
Vitória, Espírito Santo 29055-450, Brazil
Brasília, Federal District 70390-700, Brazil
Campo Grande, Mato Grosso do Sul 79080-190, Brazil
Belo Horizonte, Minas Gerais 30150-221, Brazil
Belo Horizonte, Minas Gerais 30150-320, Brazil
Belo Horizonte, Minas Gerais 31110-580, Brazil
Campinas, São Paulo 13010-001, Brazil
São Bernardo do Campo, São Paulo 09715-090, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
São José dos Campos, São Paulo 12243-280, Brazil
São Paulo, 05403-000, Brazil
Sofia, 1527, Bulgaria
Sofia, 1606, Bulgaria
Sofia, 1606, Bulgaria
Vancouver, British Columbia V5Z 1M9, Canada
North York, Ontario M6B 3H7, Canada
Montreal, Quebec H2X 0C1, Canada
Montreal, Quebec H4A 3J1, Canada
Québec, Quebec G1V 4G5, Canada
Saint-Charles-Borromée, Quebec J6E 6J2, Canada
Independencia, Santiago Metropolitan, Chile
Beijing, Beijing Municipality 100050, China
Luoyang, Henan 471000, China
Wuhan, Hubei 430022, China
Nanjing, Jiangsu 210011, China
Shanghai, Shanghai Municipality 200011, China
Shanghai, Shanghai Municipality 200240, China
Chongqing, Sichuan 400010, China
Barranquilla, Atlántico 080002, Colombia
Barranquilla, Atlántico 080020, Colombia
Valledupar, Cesar Department 200001, Colombia
Bogota, Cundinamarca 110231, Colombia
Havirov - Mesto, 736 01, Czechia
Prague, 101 00, Czechia
Praha 10 - Zabehlice, 106 00, Czechia
OYS, 90029, Finland
Besançon, 25030, France
Dijon, 21079, France
Grenoble, 38700, France
Strasbourg, 67000, France
Vandœuvre-lès-Nancy, 54511, France
Bochum, 44789, Germany
Dresden, 01277, Germany
Reinfeld (Holstein), 23858, Germany
Wermsdorf, 04779, Germany
Athens, 12462, Greece
Shatin, New Territories, Hong Kong
Miskolc, 3526, Hungary
L’Aquila, 67100, Italy
Milan, 20162, Italy
Toyoake-shi, Aichi-ken 470-1192, Japan
Toride-shi, Ibaraki 302-0022, Japan
Tsuchiura-shi, Ibaraki 300-0028, Japan
Kanazawa, Ishikawa-ken 920-8650, Japan
Urasoe-shi, Okinawa 901-2102, Japan
Suita-shi, Osaka 565-0862, Japan
Sayama-shi, Saitama 350-1305, Japan
Sayama-shi, Saitama 350-1305, Japan
Hachioji-shi, Tokyo 192-0918, Japan
Higashiyamato-shi, Tokyo 207-0014, Japan
Itabashi-ku, Tokyo 173-8606, Japan
Minato-ku, Tokyo 108-0073, Japan
Suginami-ku, Tokyo 168-0065, Japan
Yonago-shi, Tottori 683-8605, Japan
Shunan-shi, Yamaguchi 745-8522, Japan
Culiacán, Sinaloa 80230, Mexico
Tampico, Tamaulipas 89000, Mexico
Bialystok, 15-879, Poland
Bielsko-Biala, 43-316, Poland
Bydgoszcz, 85-231, Poland
Kędzierzyn-Koźle, 47-200, Poland
Krakow, 31-261, Poland
Rzeszów, 35-055, Poland
Tarnów, 33-100, Poland
Tychy, 43-100, Poland
Warsaw, 02-507, Poland
Warsaw, 04-635, Poland
Carnaxide, 2790-134, Portugal
Lisbon, 1649-035, Portugal
Matosinhos Municipality, 4464-513, Portugal
Riachos, Torres Novas, 2350-325, Portugal
Santa Maria da Feira, 4520-211, Portugal
Bucharest, 011053, Romania
Bucharest, 030167, Romania
Goyang-si, Gyeonggi-do, 10475, South Korea
Seongnam-si, Gyeonggi-do, 13620, South Korea
Wonju-si, Gangwon-do, 26426, South Korea
Ferrol, Galicia 15405, Spain
Taoyuan, 33305, Taiwan
Afyonkarahisar, 03218, Turkey (Türkiye)
Istanbul, 34854, Turkey (Türkiye)
Newcastle upon Tyne, NE1 4LP, United Kingdom
Wiltshire, BA15 1DQ, United Kingdom